OncoMatch/Clinical Trials/NCT06717711
Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers
Is NCT06717711 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Low-intensity Extracorporeal Shock Wave Therapy (LiESWT) and PDE5 inhibitor (tadalafil) for prostate carcinoma.
Treatment: Low-intensity Extracorporeal Shock Wave Therapy (LiESWT) · PDE5 inhibitor (tadalafil) — This prospective randomized controlled trial (RCT) is designed to provide high level evidence on the efficacy of Low-intensity Extracorporeal Shock Wave Therapy (Li-ESWT) in the treatment of post-Robot-Assisted (RA) Radical Prostatectomy (RP) erectile dysfunction (ED) in addition to PDE5 inhibitors (PDE5i) versus PDE5i alone. Our hypothesis is that early andrological rehabilitation that combines Li-ESWT and PDE5i could lead to faster and better recovery of valid erections for intercourse, with a greater rate of postoperative International Index of Erectile Function-5 (IIEF-5) compared to patients receiving PDE5i alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Grade: ISUP grade ≤2 (ISUP)
Prostate Cancer ISUP grade ≤2 and cT≤2 at prostate biopsy; Prostate Cancer ISUP grade ≤2 pT<3b and at final pathology
Prior therapy
Must have received: robot-assisted radical prostatectomy (nerve sparing RARP)
undergoing nerve sparing RARP
Cannot have received: pelvic radiotherapy
patients submitted to pelvic radiotherapy
Cannot have received: androgen deprivation
patients submitted to...androgen deprivation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify